Apellis Receives Negative CHMP Opinion for Pegcetacoplan for …
WEB2 days ago · WALTHAM, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has confirmed its June 2024 negative opinion on the marketing authorization application of intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age ...
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for …
WEB1 day ago · WALTHAM, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...
Europe's CHMP turns down Apellis' pegcetacoplan appeal, …
WEB1 day ago · Europe's CHMP turns down Apellis' pegcetacoplan appeal, endorses new drugs from Pfizer, ImmunoGen and Henlius By Fraiser Kansteiner Sep 20, 2024 10:06am Apellis Pharmaceuticals Syfovre CHMP ...
Apellis Receives Negative CHMP Opinion for ... - Markets Insider
WEB2 days ago · WALTHAM, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...
Apellis Says CHMP Confirms Negative Opinion For Pegcetacoplan …
WEB1 day ago · (RTTNews) - Apellis Pharmaceuticals, Inc. (APLS) announced on Friday that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has upheld its negative ...
CHMP rejects Apellis' Syfovre, says yes to Merck's Winrevair
WEBJun 28, 2024 · For the second time in six months, Europe’s CHMP has given a thumbs down to Apellis’ Syfovre for the treatment of patients with geographic atrophy.
Apellis Plans to Seek Re-Examination Following Negative CHMP …
WEBWALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...
Apellis Plans to Seek Re-Examination Following Negative
WEBWALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...
Apellis Announces Negative CHMP Opinion for Pegcetacoplan for …
WEBWALTHAM, Mass., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European...
Apellis: CHMP Once Again Recommends Against Syfovre
WEB2 days ago · The CHMP's final opinion follows two earlier negative votes this year on the drug, which is marketed as Syfovre in the U.S. and generated $154.6 million in U.S. net product revenue for Apellis in ...
Skip to content